Venowave
Commercial- Indications
- Deep vein thrombosis, Poor circulation
Company intelligence / Profile preview
Therma Bright has a diversified portfolio of medical devices and diagnostic technologies. Its Venowave VW5 device has received positive regulatory attention, including anticipated CPT/HCPCS code approvals. The company’s investment in Inretio’s Preva® ischemic stroke device has reached successful completion of three human trials. The inhaled statin therapy is in preclinical or early clinical development for respiratory indications[6][7]. Consumer product lines are being spun off into a separate public company[4].
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Therma Bright.